Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations

References

• Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129(12):1577–1585. [Internet]. Mar 23
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. [Internet].
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. [Internet].
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. [Internet].
   PubMed Web of Science ®Google Scholar
• Grimwade D, Ivey A, Huntly BJP. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41. [Internet]
   PubMed Web of Science ®Google Scholar
• de Propris MS, Raponi S, Diverio D, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10):1548–1551.
   PubMed Web of Science ®Google Scholar
• Riccioni R, Pelosi E, Riti V, et al. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. Br J Haematol. 2011;153(1):33–42.
   PubMed Web of Science ®Google Scholar
• Rollins-Raval M, Pillai R, Warita K, et al. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol. 2013;21(3):212–217.
   PubMedGoogle Scholar
• Ehninger A, Kramer M, Röllig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;13;4(6):e218–e218. [Internet]. Jun
   Google Scholar
• Angelini DF, Ottone T, Guerrera G, et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21(17):3977–3985.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Lewis I. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. J Hematol Oncol. 2016;9(1):61.
   PubMedGoogle Scholar
• Bras AE, Haas V, Stigt A, et al. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytom Part B Clin Cytom. 2019;96(2):134–142. [Internet]. Mar 18
   PubMed Web of Science ®Google Scholar
• Haubner S, Perna F, Köhnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74. [Internet]
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266. [Internet]
   PubMed Web of Science ®Google Scholar
• Mori Y, Yoshimoto G, Kumano T, et al. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation. Eur J Haematol. 2007;79(1):17–24.
   PubMed Web of Science ®Google Scholar
• Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115(18):3776–3786. [Internet]
   PubMed Web of Science ®Google Scholar
• Kalina T, Flores-Montero J, Van Der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986–2010.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–1975.
   PubMed Web of Science ®Google Scholar
• Rausei-Mills V, Chang KL, Gaal KK, et al. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am J Clin Pathol. 2008;129(4):624–629.
   PubMed Web of Science ®Google Scholar
• Chauhan PS, Bhushan B, Mishra AK, et al. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. Med Oncol. 2011;28(2):544–551.
   PubMed Web of Science ®Google Scholar
• Dalal BI, Mansoor S, Manna M, et al. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Clin Lymphoma, Myeloma Leuk. 2012;12(4):274–279.
   PubMed Web of Science ®Google Scholar
• Chauhan PS, Ihsan R, Singh LC, et al. Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features. Dis Markers. 2013;35(5):581–588.
   PubMedGoogle Scholar
• Baqai J, Crisan D. Correlation of FLT3 mutations with expression of CD7 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol. 2015;23(2):104–108.
   PubMedGoogle Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United King. Blood. 2001;98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–2784.
   PubMed Web of Science ®Google Scholar
• Bain BJ, Béné MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol. 2019;141(4):232–244.
   PubMed Web of Science ®Google Scholar
• Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15(8):1161–1164.
   PubMed Web of Science ®Google Scholar
• Novotny JR, Nückel H, Dührsen U. Correlation between expression of CD56/NCAM and severe leukostasis in hyperleukocytic acute myelomonocytic leukaemia. Eur J Haematol. 2006;76(4):299–308.
   PubMed Web of Science ®Google Scholar
• Aref S, Abousamara N, El-Helaly E, et al. Clinical significance of CD200 and CD56 expression in patients with acute myeloid leukemia. Asian Pacific J Cancer Prev. 2020;21(3):743–748.
   PubMedGoogle Scholar
• Jiang A, Jiang H, Brandwein J, et al. Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leuk Res. 2011;35(4):492–498.
   PubMed Web of Science ®Google Scholar
• Xian J, Shao H, Chen X, et al. Nucleophosmin mutants promote adhesion, migration and invasion of human leukemia THP-1 cells through MMPs up-regulation via Ras/ERK MAPK signaling. Int J Biol Sci. 2016;12(2):144–155.
   PubMed Web of Science ®Google Scholar
• Matarraz S, Almeida J, Flores-Montero J, et al. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytom Part B Clin Cytom. 2017;92(3):218–227.
   PubMed Web of Science ®Google Scholar
• Sasca D, Szybinski J, Schüler A, et al. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. Blood. 2019;133(21):2305–2319.
   PubMed Web of Science ®Google Scholar
• Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740–3746.
   PubMed Web of Science ®Google Scholar